Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth
Starting soon · Phase 2/Phase 3 · Has a placebo group
Conditions studied: Telogen Effluvium, Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia, Male Pattern Baldness, Androgenetic Alopecia, Androgenetic Alopecia (AGA)
In brief
The primary objective of the study is to assess the safety and efficacy of DA-001 as a treatment for Hair Shedding Reduction and Hair Re-Growth
Key facts
- Study ID
- NCT06648850
- Run by
- Applied Biology, Inc.
- People needed
- 1120
- Starts
- 2026-05-01
- Expected to finish
- 2027-04-26
- Last updated by the study team
- 2026-04-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age 18 or older
- Diagnosed with telogen effluvium
- Willing and able to apply the treatment as directed, comply with study
- Otherwise healthy
- Able to give informed consent
You may not qualify if…
- A medical history that may interfere with study objectives
- Women who are pregnant, lactating, or planning to become pregnant during the study period
- Subjects who have experienced a clinically important medical event within 90 days of the visit (e.g., stroke, myocardial infarction, etc)
- Subjects who have known allergies to any excipient in DA-001
- Subjects who are currently participating in another clinical study or have completed another clinical study with an investigational drug or device in the treatment area within 30 days prior to study treatment initiation
- Subjects who have used any topical prescription medications in the treatment area within 30 days prior to study treatment initiation
- Subjects who have had a dermatological procedure such as surgery in the treatment area within 30 days prior to study treatment initiation
- Subject is unable to provide consent or make the allotted clinical visits
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.